Axsome Therapeutics, Inc. has announced the topline results of the Paradigm Phase 3 proof-of-concept trial of Solriamfetol in major depressive disorder (MDD) with and without excessive daytime ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback